Evidence map›Paper›PMID 35943710›Full record

ArticleMolecular neurobiology2022

Adenosine A

Heba Nasr Shalaby, Hala Fahmy Zaki, Afaf Abd Almonim Ain-Shoka, Reham Atef Mohammed

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Endothelial adenosine AFrontiers in medicine · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Heba Nasr ShalabyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. heba.nasr@pharma.cu.edu.eg.ORCID http://orcid.org/0000-0002-3879-7022
Hala Fahmy ZakiDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Afaf Abd Almonim Ain-ShokaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Reham Atef MohammedDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenosinergic system dysfunction is implicated in the pathophysiology of multiple neuropsychiatric disorders including mania and bipolar diseases. The established synergistic interaction between A

Indexed as

Adenosine A2 Receptor AntagonistsManiaMethylphenidateReceptor, Adenosine A2AAnimalsAntimanic Agentsbeta CateninGlycogen Synthase Kinase 3 betaLithiumProto-Oncogene Proteins c-aktPyrimidinesRatsTriazoles5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidineAdenosine A2 Receptor AntagonistsAntimanic Agentsbeta CateninGlycogen Synthase Kinase 3 betaLithiumMethylphenidateProto-Oncogene Proteins c-aktPyrimidinesReceptor, Adenosine A2ATriazolesAdenosineGSK-3βManiaPKC-αPrefrontal cortexSNAP-25

Identifiers

PMID35943710
PMCPMC9463338
OpenAlexW4292359887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.